Skip to content

Effect of genetic polymorphism on nasopharyngeal carcinoma chemoradiotherapy reaction

Effect of genetic polymorphism on nasopharyngeal carcinoma chemoradiotherapy reaction

Status
Recruiting
Phases
Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-OPC-14005257
Enrollment
Unknown
Registered
2014-09-18
Start date
2014-09-22
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

nasopharyngeal carcinoma

Interventions

Two cohorts:chemoradiotherapy

Sponsors

the Third Xiangya Hospital, Central South University
Lead Sponsor

Eligibility

Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1.pathological examination confirmed the diagnosis of nasopharyngeal carcinoma patients; 2. patients age 18-75 years; 3.without metastasis; 4.by clinical, imaging (X-ray, CT/MRI) detection is completely unable to operation resection; 5.received radiotherapy before did not accept the other anti-tumor therapy, complete radical treatment; follow-up survey received;6.after treatment; signed 7 hospital chemotherapy related to informed consent.

Exclusion criteria

Exclusion criteria: 1.do not meet the inclusion criteria; 2.pregnant or lactating patients; 3.patients with active infections; 4.associated with serious diseases such as cirrhosis of the liver, bleeding tendency, with a clear heart rhythms and heart failure patients; 5.have a history of cancer or complicated by other tumor patients.

Design outcomes

Primary

MeasureTime frame
genetic polymorphism;curative effect;toxicity reaction;

Countries

China

Contacts

Public ContactCheng-Xian Guo
gchxyy@163.com+86 0731-88618338

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 12, 2026